Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

378 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N. Seersholm N, et al. Among authors: banik n. Eur Respir J. 1997 Oct;10(10):2260-3. doi: 10.1183/09031936.97.10102260. Eur Respir J. 1997. PMID: 9387950 Clinical Trial.
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M; “Aktion Bronchialkarzinom” (ABC Study Group). Fink TH, et al. Among authors: banik n. J Thorac Oncol. 2012 Sep;7(9):1432-9. doi: 10.1097/JTO.0b013e318260de75. J Thorac Oncol. 2012. PMID: 22895140 Clinical Trial.
Properties of the COPD assessment test in a cross-sectional European study.
Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, Banik N. Jones PW, et al. Among authors: banik n. Eur Respir J. 2011 Jul;38(1):29-35. doi: 10.1183/09031936.00177210. Epub 2011 May 12. Eur Respir J. 2011. PMID: 21565915
378 results